GlassScriptPhysician profile
Grace Razavian
NPI 1417481631
$5,111.92
in general payments reported to CMS, 2019-2025
33 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.15 · 2020: $59.20 · 2021: $34.55 · 2022: $81.57 · 2023: $2,169 · 2024: $1,545 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,340 · Travel and Lodging: $1,260 · Education: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,339.80 |
| Travel and Lodging | $1,260.49 |
| Education | $247.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $746.40 | 2023 | Cook |
| Cook Incorporated | $740.34 | 2023 | Fiber Dust |
| Sumitomo Pharma America, INC. | $562.89 | 2024-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $547.38 | 2023-2025 | Erleada |
| Dendreon Pharmaceuticals LLC | $343.19 | 2023 | Provenge |
| Boston Scientific Corporation | $224.48 | 2019-2024 | Watchman Access System, Rezum Generator |
| Intuitive Surgical, INC. | $179.09 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $163.99 | 2024-2025 | |
| Palette Life Sciences, INC. | $150.72 | 2023 | |
| Laborie Medical Technologies Corp. | $147.19 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Tolmar, INC. | $134.42 | 2024-2025 | Eligard, Jatenzo |
| Progenics Pharmaceuticals, INC. | $133.08 | 2023-2025 | Pylarify |
| Ferring Pharmaceuticals INC. | $114.19 | 2024-2025 | Adstiladrin |
| Pfizer INC. | $113.36 | 2024-2025 | |
| Accord Healthcare, INC. | $101.94 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Srs Medical Systems, INC. | $95.19 | 2024 | Urocuff-Dc Disposable, Single, Ct3000 Pro Base Unit |
| Sun Pharmaceutical Industries INC. | $73.78 | 2023-2024 | Yonsa |
| Immunitybio, INC. | $66.86 | 2024-2025 | |
| Olympus America INC. | $65.72 | 2024 | Soltive, Endocapsule Recorder, Cysto-Nephro Videoscope |
| Blue Earth Diagnostics | $49.45 | 2023-2024 | |
| Conmed Corporation | $44.51 | 2020 | |
| Astellas Pharma US INC | $43.30 | 2023-2024 | Xtandi |
| Merck Sharp & Dohme LLC | $37.89 | 2024-2025 | Zerbaxa, Lynparza |
| Urogen Pharma, INC. | $36.59 | 2021-2025 | |
| Abc Home Medical Supply, INC. | $30.75 | 2025 | |
| Daiichi Sankyo INC. | $28.57 | 2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $22.29 | 2024 | |
| Teleflex LLC | $21.57 | 2024 | Urolift |
| Myovant Sciences INC. | $20.78 | 2021 | |
| Bluewind Medical | $20.16 | 2024 | Revi |
| Medtronic, INC. | $19.60 | 2024 | Interstim |
| Neurelis, INC. | $18.32 | 2025 | Valtoco |
| Myriad Genetic Laboratories, INC. | $13.93 | 2024 | Prolaris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Razavian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.